Form 4: CareDx CEO John Hanna Executes Stock Sale

CareDx President and CEO John Walter Hanna Jr. sold 10,282 shares of common stock at $21.12 per share.

Summary

• John Walter Hanna Jr., President and CEO of CareDx, Inc., sold 10,282 shares of common stock.
• The transaction occurred on April 16, 2026, at a price of $21.12 per share.
• Following the sale, the reporting person retains beneficial ownership of 676,475 shares.
• The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on December 13, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned, non-discretionary trading program.

Positives

• The sale was conducted via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The transaction represents a reduction in the CEO's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance events and generally do not reflect a change in strategic direction or internal sentiment regarding company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to manage personal liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the CEO's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

CareDx, CDNA, Insider Trading, Form 4, Executive Compensation, Biotech